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Understanding the mechanisms underlying the differences in renal decline between men and 
women may improve sex-specific clinical monitoring and management. To this end, we aimed to 
compare the slope of renal function decline in older men and women in CKD stage 4-5, taking into 
account informative censoring related to the sex-specific risks of mortality and dialysis initiation.  
Methods 
The EQUAL study is an observational prospective cohort study in stage 4-5 CKD patients ≥65 years 
not on dialysis. Data on clinical and demographic patient characteristics were collected between 
April 2012 to December 2018. eGFR was calculated using the CKD-EPI equation. eGFR trajectory by 
sex was modelled using linear mixed models, and joint models were applied to deal with informative 
censoring. 
Results 
We included 7801 eGFR measurements in 1682 patients over a total of 2911 years of follow-up. 
Renal function declined by 14.0% (95% CI 12.9%-15.1%) on average each year. Renal function 
declined faster in men (16.2% per year, 95% CI 15.9%-17.1%) compared with women (9.6% per year, 
95% CI 6.3%-12.1%), which remained largely unchanged after accounting for various mediators, and 
for informative censoring due to mortality and dialysis initiation. Diabetes was identified as an 
important determinant of renal decline specifically in women.  
Conclusion 
In conclusion, renal function declines faster in men compared with women, which remained similar 
after adjustment for mediators, and despite a higher risk of informative censoring in men. We 





What is already known about this subject:  
• It is known that the epidemiology of chronic kidney disease (CKD) differs by sex, however, 
the current evidence on sex-specific slopes of renal decline in advanced CKD remains 
inconclusive. 
• Studying renal function decline by sex is complicated by informative censoring caused by 
sex-specific risks of mortality and dialysis initiation. 
 
 
What this study adds:  
• Men progress faster than women, even after adjustment for important mediators, and 
despite having a higher risk of censoring. 
• Diabetes is an important determinant of renal decline, with a disproportional negative 
impact specifically in women. 
 
What impact this may have on practice or policy:  
• Our results help understand the mechanisms underlying the differences in renal function 
decline between the sexes, and help achieve individualized and sex-specific management 









The epidemiology of chronic kidney disease (CKD) differs by sex. Population-based studies across the 
globe consistently show a higher prevalence of CKD in women compared with men 1–7, yet 
approximately 60% of those starting renal replacement therapy (RRT) for end-stage kidney disease 
(ESKD) are men 8,9. This paradox has several potential explanations 10. First, the longer life 
expectancy in women along with the natural decline of glomerular filtration rate with age may partly 
explain the higher prevalence of CKD in women. Second, several (population-based) studies 11–14, as 
well as a large meta-analysis of studies in non-diabetic CKD patients 15, point towards a faster decline 
of renal function in men. In contrast, others have demonstrated a more rapid progression in women 
in various (sub) populations 16–18, whereas some found no difference between the sexes at all 19,20. A 
meta-analysis of randomized controlled trials found that women progress at an equal speed as men, 
with adjusted analyses even suggesting a faster progression in women 21. Given these inconclusive 
results, it is clear that the estimated sex-specific decline in renal function depends on the population 
studied; CKD stage, the presence of diabetes mellitus, (post-menopausal) age, population-based 
cohorts versus referred patients, are all factors that likely contribute to the variation in current 
evidence. 
Studying renal function decline by sex is complicated by a sex-specific selection processes caused by 
a higher mortality risk in men across all ranges of pre-ESKD eGFR 22,23. The effect of eGFR decline and 
albuminuria on mortality risk seems stronger in women, adding complexity to the selection process 
22. Furthermore, as men and women start dialysis at different levels of eGFR 24, censoring at dialysis 
initiation may be deemed informative when studying CKD progression. Consequently, it is important 
when investigating this topic to take into account informative censoring caused by mortality and 
dialysis initiation, as the estimated slopes of renal function decline by sex may otherwise be biased. 
Understanding the mechanisms underlying the differences in renal function decline between the 
sexes may aid sex-specific clinical monitoring and management. To date, very few studies have 
investigated renal function decline by sex specifically during pre-dialysis stages 4-5 in referred CKD 
patients of older age, and none have taken into account the potential bias caused by the sex-specific 
risk of mortality and dialysis initiation 25. Consequently, here we aim to compare the slope of renal 
function decline in older men and women with advanced CKD, taking into account informative 
censoring due to mortality and dialysis. As a secondary aim, we will explore sex-specific 








Study design and population 
The EQUAL study is an ongoing observational cohort study including stage 4-5 CKD patients not on 
dialysis receiving routine medical care in Germany, Italy, the Netherlands, Poland, Sweden, and the 
United Kingdom. Patients of 65 years of age and older were included with an incident estimated 
glomerular filtration rate (eGFR) < 20 ml/min/1.73m² calculated by the Modification of Diet in Renal 
Disease equation. Patients were excluded if the drop in eGFR resulted from an acute event or if they 
had previously received dialysis or a kidney transplant. Approval was obtained from the medical 
ethical committees in each country. Informed consent was obtained from all patients. A full 
description of the study has been published elsewhere 26.  
 
Data collection 
Clinical data were collected between April 2012 to December 2018 on patient demographics, 
primary renal disease, laboratory data, and cardiovascular risk factors (smoking status, body mass 
index, haemoglobin, blood pressure, cholesterol, and diabetes mellitus). Data on the following pre-
existing cardiovascular comorbid conditions were also collected (definitions provided in 
supplement); cerebrovascular disease, peripheral vascular disease, myocardial infarction, angina 
pectoris, congestive heart failure, left ventricular hypertrophy, hypertension, and cardiac 
arrhythmias. Study visits were scheduled at 6-month intervals, and patients were followed until 
dialysis initiation, kidney transplantation, death, refusal for further participation, loss to follow-up, 
or end of follow-up. The eGFR was calculated from serum creatinine level standardized to isotope 
dilution mass spectrometry using the CKD-EPI equation 27. In addition, GFR was estimated during 
follow-up from routine 24-hour urine collection by taking the average of creatinine clearance and 
urea clearance, normalized to body surface area following the Dubois & Dubois formula. Albumin-
creatinine ratio was also determined following routine 24-hour urine collection or a single sample if 
24h urinary collection was unavailable. Primary kidney disease was classified using the codes of the 
European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) and 
grouped as glomerulonephritis, diabetes mellitus, tubulo-interstitial disease, hypertension, and 
miscellaneous kidney diseases.  
 
Statistical analysis 
Patient characteristics were reported by sex as mean values with standard deviations for normally 
distributed continuous variables, as medians with interquartile ranges for skewed continuous 
variables, and as proportions for categorical variables. Linear mixed models were used to model the 
7 
 
eGFR trajectory. A random intercept was included to capture the variation in eGFR baseline value 
between patients, and a random slope for time to capture variability in the patient's eGFR trajectory. 
Due to non-linear patient trajectories of eGFR, the latter was included as a cubic B-spline with two 
equally spaced knots positioned between the minimum and maximum of follow-up. The unadjusted 
model includes time, sex, and their interaction, and describes the sex-specific trajectory of eGFR 
over time. In subsequent models, we investigate to which extent the effect of sex on the eGFR 
trajectory is mediated by various groups of a priori defined covariates (i.e. mediators). All models 
were adjusted for baseline eGFR and age at inclusion.  
 
We followed patients until death or dialysis initiation. Missing eGFR values may be introduced when 
patients drop-out of the study due to mortality or are censored due to dialysis initiation. As the level 
of renal function is related to these events, drop-out is deemed informative 28–30. We applied joint 
models for longitudinal and time-to-event data to avoid biased estimates of eGFR decline 31. The 
joint model links the linear mixed model described above to a Cox survival model, which captures 
the risk of either mortality or dialysis. In this manner, the joint model informs the longitudinal eGFR 
trajectory on missingness caused by either of these events. To determine whether the difference in 
eGFR slope between men and women had changed after taking into account informative censoring 
due to mortality or dialysis, we tested for equality between the time-sex interaction coefficients in 
the linear mixed model and joint model using a Z-score test 32. 
Sex-specific determinants of eGFR decline were studied through effect modification using 
interaction analyses, specifically through 3-way interactions between sex, time, and the 
characteristics of interest. Q-Q plots were used to check whether the residuals were normally 
distributed, and eGFR was log-transformed to fulfil this assumption. Consequently, regression 
coefficients were exponentiated and interpreted as the mean percent change in eGFR per year. Only 
complete cases were analysed, and missing values are reported in the supplement. All analyses were 
performed with SAS version 9.4 and R version 3.4.1. 
Sensitivity analyses 
We performed a number of sensitivity analyses. First, in addition to the CKDEPI equation, we also 
repeated the analyses using the Full Age Spectrum equation and the revised Lund-Malmö equation 
to estimate GFR 33,34. Second, we studied the association between sex and GFR decline estimated 
from 24-hour urine collection. Third, as age is an important variable in all estimating GFRs, we also 
considered the relationship between sex and 1/creatinine over time. Last, due the wide range in 






Patient characteristics  
Table 1 describes the baseline characteristics of 1682 patients by sex. On average, patients were 76 
years old at inclusion (IQR 71-81), two-thirds were men, and the eGFR at baseline was 17.0 
ml/min/1.73m2 (IQR 14.5-20.4). Women were older, had a slightly higher BMI, higher values of 
serum calcium, cholesterol, and potassium, but lower levels of haemoglobin. Diabetes and 
glomerular disease accounted for a lower proportion of primary renal disease in women compared 
with men, whereas tubulo-interstitial disease and hypertension were more common in women. 
Women had higher baseline renal function, and lower albumin creatinine ratio (ACR). Regarding 
comorbidity, more men had diabetes, peripheral vascular disease, myocardial infarction, and angina 
pectoris.  
The effect of sex on the eGFR trajectory 
We included 7801 eGFR measurements over a total of 2911 years of follow-up, with a median of 4 
(IQR 2-7) measurements per patient, and a median follow-up time of 18.6 months (IQR 6.7 – 32.6). 
Renal function declined 14.0% (95% CI 12.9%-15.1%) on average each year. Figure 1A shows a faster 
unadjusted annual decline in renal function in men (16.2% per year, 95% CI 15.9%-17.1%) compared 
with women (9.6% per year, 95% CI 6.3%-12.1%), with a difference of 6.6% (95% CI 4,3%-9,1%). 
These estimates remained largely unchanged after accounting for various groups of mediators (table 
2). For the purpose of comparison with existing literature, we determined the linear sex-specific 
slopes of renal function decline, without log-transformation, as -1.82 (95% CI -1.63--2.01) 
ml/min/1.73m2 per year for men and -0.91 (95% CI -0.40--1.43) ml/min/1.73m2 per year for women. 
Sensitivity analyses using GFR estimated following routine 24-hour urine collection, 1/creatinine, and 
eGFR calculated using the Full Age Spectrum and the revised Lund-Malmö equations provided similar 
results . Estimated renal function decline in a sub-group of patients with at least 1 year of follow-up 
was also similar to the main results (supplement). 
The effect of sex on the eGFR trajectory adjusted for informative censoring 
Figure 1B shows the eGFR trajectory in men and women after accounting for informative censoring 
due to death or dialysis initiation. The adjusted trajectories represent the average eGFR trajectory in 
the hypothetical situation that all patients had remained alive / had not started dialysis. After 
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accounting for death (5-year cumulative incidence of 21.4% in men and 19.6% in women, p-value = 
0.32), the difference in renal decline between men (16.1% per year, 95% CI 15.0%-17.1%) and 
women (9.5% per year, 95% CI 6.3%-12.6%) remained 6.6% (p-value for change in coefficient = 0.97). 
Accounting for drop-out due to dialysis initiation (5-year cumulative incidence of 31.9% in men and 
21.4% in women, p-value for difference <.0001) also had little effect on the difference in renal 
function decline between men (17.2% per year, 95%CI 16.1%-18.5%) and women (10.4% per year, 
95% CI 6.9%-14.2%), increasing the difference in slope between men and women marginally from 
6.6% to 6.8% (p-value for change in coefficient = 0.81). 
The sex-specific determinants of the eGFR trajectory 
We identified effect modification by age, diabetes, and myocardial infarction at inclusion on the 
slope of renal function decline by sex. We found that women of older age had slower declines in 
renal function compared with younger women (figure 2A), whereas age had little effect on renal 
decline in men (p-value for interaction= 0.03). In addition, women with diabetes had significantly 
faster declines in renal function compared with non-diabetics, whereas this was not the case in men 
(figure 2B, p-value for interaction = 0.05). The differential effect of diabetes seemed more 
pronounced in women under the age of 82 (p-value for interaction = 0.02, supplementary figure 1). 





In our population of elderly CKD stage 4 and 5 patients not on dialysis, we demonstrate a faster 
decline of renal function in men compared with women, which persisted after taking into account 
important mediators. By applying joint models to account for the sex-specific risks of informative 
censoring due to death and dialysis, we demonstrate that men progress faster than women despite 
having a higher risk of drop-out. Furthermore, we identified diabetes as an important determinant of 
renal decline specifically in women, demonstrating that renal function in female diabetics 
deteriorated at a similar pace as in men. Interestingly, older women had slower declines of renal 
function, indicative of a certain degree of selection bias in our cohort. 
 
To our knowledge, this is the first study to explore renal decline by sex in a referred cohort of 
incident CKD patients with an eGFR of <20 ml/min/1.73m2. We found that renal function in men 
declined approximately twice as fast as in women (-1,82 ml/min/1.73m2 per year and -0,89 
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ml/min/1.73m2 per year, respectively), which remained similar after adjustment for various 
mediators and informative censoring. Comparable studies on sex-specific renal decline during the 
transition period from stage 4-5 CKD to dialysis are scarce11,25. Nonetheless, our results are in line 
with studies published in cohorts consisting of patients in earlier stages of CKD15; a Swedish 
population-based study of CKD stage 3 patients estimated similar differences in renal declines 
between men (-1.26 ml/min/1.73m2 per year for a 70-year old) and women (-0.76 ml/min/1.73m2 
per year) 13. More recently, in a referred cohort of CKD stage 2 and 3 patients, the CRIC study also 
found faster declines in men (-1.43 ml/min/1.73m2 per year) compared with women (-1.09 
ml/min/1.73m2 per year), although this difference was somewhat smaller compared to our 
estimates 12. Even in the ‘healthy’ general population (cohort baseline eGFR of 80.7 ml/min/1.73m2), 
the PREVEND study found an eGFR slope of -0.55 ml/min/year/1.73m2 in men and -0.33 
ml/min/year/1.73m2 in women 14. Altogether, most available evidence points towards a faster 
decline of renal function in men, seemingly regardless of CKD stage. Nonetheless, a handful of 
studies exist that have found either a faster progression in women 16 or no difference at all between 
the sexes 19,20. One of these studies, a large meta-analysis of randomized controlled trials, found that 
women progress at an equal speed as men, with adjusted analyses (baseline creatinine, blood 
pressure, urinary protein, age, and treatment assignment) suggesting a faster progression in women 
21, although this discrepancy may be attributed to stringent patient selection common to RCTs and 
erroneous adjustment within the causal pathway.  
This sex difference in renal decline has several potential explanations related to biological and/or 
sociocultural aspects 10. Risk factors related to lifestyle, such as a poor diet and smoking, may partly 
be responsible for faster decline as seen in men 18,35. Although more men had a history of smoking 
and a higher burden of cardiovascular co-morbidities in our cohort, adjustment for these factors had 
little effect on the sex difference in renal decline. Others have demonstrated differential effects of 
albuminuria, cholesterol, blood pressure, and glycaemic control, on renal function decline in men 
and women 14,16,35, although most of these studies applied methodology corresponding to prognostic 
research, thus not contributing to mechanistic evidence. Lastly, sex hormones also likely play a role, 
as animal studies have demonstrated renoprotective effects of oestrogens and damaging effects of 
testosterone 25,36–38. 
We demonstrate that diabetes has a stronger effect on renal decline in women compared with men, 
to the extent that renal decline was similar between the sexes in those with diabetes. The literature 
surrounding this topic is inconsistent, with some reporting faster declines in diabetic men39,40, and 
others finding no differences between the sexes 41. In line with our findings, a Japanese cohort of 
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type 2 diabetics described faster declines in women (-3.5 per year) compared with men (-2.0 per 
year), attributing this finding to a poorer metabolic control in women 42. Similarly, a UK randomised 
control trial in type 2 diabetics found that women had an 88% increased risk over men of declining 
to <60 ml/min 43. Moreover, excess mortality risk in diabetic women has been described in the 
dialysis population 44, as well as in non-renal cohorts 45,46, confirming a disproportional negative 
impact of diabetes in women. Diminished protection of oestrogens in the hyperglycemic state may 
explain this disparate effect, even though the women in our population were likely post-menopausal 
47.  
 
Missing eGFR values are introduced over time as patients are censored due to dialysis initiation or 
death. As the level of renal function is related to these events, censoring is deemed informative 28. 
More importantly, as the risks of dialysis initiation or death are specific to men and women, 
informative censoring may affect the estimated slopes for men and women differentially, potentially 
introducing bias. We are unaware of any previous studies that have taken into account the sex-
specific risks of dropout when studying renal decline by sex. Here, we were able to account for this 
issue by modelling both eGFR decline and the risk of drop-out simultaneously, providing eGFR slopes 
corrected for both censoring due to death and dialysis. As the risk of death did not differ 
substantially between men and women in our cohort, adjustment had little effect on the difference 
in slopes between men and women. However, as Nitsch et al demonstrated in their meta-analysis, 
the mortality risk difference between men and women is far larger in earlier stages of CKD 22. In such 
populations, accounting for mortality would have likely had a larger effect on the difference in renal 
slopes between men and women, accounting for more of the difference in renal decline compared 
to our cohort. Conversely, accounting for censoring caused by dialysis initiation led to marginally 
steeper adjusted slopes, reflecting the faster renal decline in patients that were censored due to 
dialysis initiation. As the risk of dialysis was higher in men, the unbiased difference in renal function 
decline between the sexes was amplified slightly after accounting for this event, although this 
change in effect was not statistically significant. 
 
Studying renal decline by sex is complicated by a sex-specific selection process throughout the pre-
dialysis period. Contrary to our expectations, we found slower renal declines in older women. The 
literature on the effect of age on renal decline is inconsistent, with some reporting faster renal 
declines with increasing age 17,48, and others reporting the opposite49,50. Potential explanations for 
our findings may be a differential mortality rate in men and women (prior to inclusion) which may be 
inclined to select the healthier surviving women with slowly progressing CKD. One may also 
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hypothesize that this finding may be caused by a sex-dependent decrease in muscle mass with age, 
biasing our estimated glomerular filtration rates. Lastly, considering all patients in the EQUAL cohort 
are referred, there may be selection mechanisms at play in the referral patterns. 
 
The main strength of our study is that we apply joint models to deal with informative censoring 
caused by mortality and dialysis initiation, providing unbiased estimates of renal decline. 
Furthermore, patients in our cohort were prospectively included when their eGFR dropped below 
the pre-defined level of 20 ml/min, thus minimizing the risk of survivor bias. Our study is also subject 
to several limitations. Preferably, we would have used measured GFR by a reference method to 
estimate the slope of renal decline, however, measuring GFR with a tracer technology was 
unfortunately not feasible in a cohort study of the size of EQUAL.. The use of eGFR in the main 
analysis may partly reflect muscle mass, which may disproportionately bias eGFR estimates in 
women 51. Nonetheless, others have shown mGFR to perform similarly to eGFR. Lastly, due to the 
observational nature of our study, residual confounding may play a role, and therefore the results 
should be interpreted accordingly. 
In older patients with advanced CKD, we demonstrate faster declines in renal function in men 
compared with women, even after adjustment for multiple groups of mediators. Importantly, 
informative events such as death and dialysis initiation explained little of the difference in renal 
decline between the sexes in our advanced CKD cohort. In diabetics, however, both men and women 
declined at a similar rate, demonstrating a disproportional negative impact of diabetes in women. 
Our results help understand the mechanisms underlying the differences in renal function decline 
between the sexes and warrant further research to develop the sex-specific interventions needed to 
achieve individualized management and treatment. 
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Table 1. Baseline patient characteristics by sex. 
  Overall (n=1682) Men (n=1099) Women (n=583) 
p-
value 
Demographics         
Age (mean (SD))  76.30 (6.76)  75.97 (6.45)  76.94 (7.28)  0.006 
Primary renal disease n (%)         
  Diabetes    341 (20.5)     238 ( 21.9)     103 ( 17.9)   0.006 
  Glomerular disease    152 ( 9.1)     111 ( 10.2)      41 (  7.1)    
  Tubulo-interstitial disease    138 ( 8.3)      76 (  7.0)      62 ( 10.8)    
  Hypertension    596 (35.8)     378 ( 34.7)     218 ( 37.9)    
  Miscellaneous renal disorders    436 (26.2)     285 ( 26.2)     151 ( 26.3)    
Weight (kg) (mean (SD))  79.70 (17.16)  83.44 (16.10)  72.51 (16.88) <0.001 
Height (cm) (mean (SD)) 167.57 (9.94) 172.17 (7.86) 158.81 (7.25) <0.001 
BMI (kg/m2) (mean (SD))  28.42 (5.34)  28.20 (4.81)  28.86 (6.23)  0.023 
Blood chemistry          
Albumin (g/dL) (mean (SD))  37.70 (5.91)  37.66 (5.89)  37.78 (5.97)  0.708 
Calcium (mmol/L) (mean (SD))   2.24 (0.32)   2.23 (0.32)   2.27 (0.33)  0.013 
Cholesterol (mmol/L) (mean (SD))   4.53 (1.28)   4.34 (1.17)   4.89 (1.41) <0.001 
PO4 (mmol/L) (mean (SD))   1.30 (0.32)   1.30 (0.33)   1.31 (0.30)  0.303 
Potassium (mmol/L) (mean (SD))   4.64 (0.61)   4.67 (0.62)   4.60 (0.60)  0.037 
Cardiovascular         
Systolic blood pressure (mmHg) (mean 
(SD)) 142.85 (21.96) 143.31 (21.61) 141.99 (22.61)  0.245 
Diastolic blood pressure (mean (SD))  73.83 (11.26)  74.00 (11.35)  73.49 (11.10)  0.379 
Hb (g/dL) (mean (SD))   0.72 (0.09)   0.73 (0.10)   0.71 (0.09) <0.001 
Current smoker n(%)    119 ( 9.3)      82 (  9.7)      37 (  8.4)   0.538 
Ex-smoker n(%)    752 (63.1)     587 ( 74.5)     165 ( 40.8)  <0.001 
Renal function         
CKDEPI (ml/min/1.73m2) (median [IQR])  17.01 [13.79, 20.11]  16.69 [13.67, 19.63]  17.63 [14.40, 21.08] <0.001 
MDRD (ml/min/1.73m2) (median [IQR])  18.57 [15.27, 21.92]  18.45 [15.05, 21.62]  18.99 [15.54, 22.62]  0.036 
ACR (median [IQR])  33.67 [4.90, 154.67]  41.36 [7.47, 161.10]  19.66 [2.99, 119.00]  0.002 
Comorbidities         
Diabetes n(%)    693 (42)     480 ( 44.5)     213 ( 37.4)   0.006 
Chronic heart failure n(%)    290 (18.1)     195 ( 18.7)      95 ( 17.0)   0.443 
Cerebrovascular disease n(%)    257 (15.7)     171 ( 15.9)      86 ( 15.3)   0.781 
Peripheral vascular disease n(%)    279 (17.2)     203 ( 19.2)      76 ( 13.5)   0.005 
Myocardial infarction n(%)    287 (17.4)     222 ( 20.6)      65 ( 11.4)  <0.001 
Angina pectoris n(%)    239 (14.7)     178 ( 16.8)      61 ( 10.9)   0.002 
Left ventricular hypertrophy n(%)    349 (23.7)     244 ( 25.3)     105 ( 20.8)   0.062 
Atrial fibrillation n(%)    297 (18.2)     190 ( 17.9)     107 ( 18.9)   0.644 





Table 2. The average annual percent decline in eGFR by sex, adjusted for various groups of 
mediators.  










Figure 1B. The average eGFR trajectory by sex (LMM) adjusted for censoring due to death (JM: 
Death) and dialysis (JM: Dialysis). The adjusted trajectories represent the average eGFR trajectory in 
the hypothetical situation that all patients had remained alive / had not started dialysis. JM: Joint 
Model, LMM: linear mixed model. The top group of lines correspond to the eGFR trajectory in 
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